학술논문
Effectiveness and tolerability of Perindopril plus Amlodipine single pill combination in Nigeria: The 13 City Hypertension Study
Document Type
Academic Journal
Author
Ojji, Dike; Ansa, Victor; Ale, Boni; Sani, Mahmoud; Obasahan, Austine; Alagbe, Sola; Williams, Rotimi; Aknitomide, Tony; Okoye, Innocent; Umuerri, Ejiroghene; Nwafor, Eze; Mbakwem, Amam; Amadi, Casmir; Shedu, Lamkur; Familoni, Ranti; Olunuga, Taiwo; Inofomoh, Francisca; Osuji, Ukachukwu; Omejua, Godwin; Azubuike, Benjamin; Ohihoin, Esther; Anakwe, Raphael
Source
SA Heart. April 2022, Vol. 19 Issue 1, p6, 7 p.
Subject
Language
English
ISSN
1996-6741
Abstract
INTRODUCTION Hypertension specifically contributes to the burden of heart disease, cerebrovascular disease, kidney failure and premature mortality and disability.(1,2) Hypertension is a global challenge with more than a quarter of [...]
Background: There is no large-scale study that has shown the efficacy of single pill combination (SPC) anti-hypertensive medications in black African population. We therefore evaluated the blood pressure (BP) lowering efficacy and the tolerability of Perindopril plus Amlodipine SPC in black African patients. Methods: It was a multi-centre, prospective, observational programme among hypertensive patients using different doses of Perindopril and Amlodipine. Primary endpoint was assessed as the change in mean sitting systolic and diastolic BPs from baseline to 3 months. Results: 937 patients (55.7% female) were analysed, and the mean age was 56.4 [+ or -] 12.7 years. Systolic and diastolic BPs were significantly reduced by 17.3/9.4mmHg, 21.1/10.8mmHg mmHg and 24.6/12.7mmHg at 4, 8 and 12 weeks respectively compared to baseline value (p Conclusions: Perindopril plus Amlodipine SPC provided clinically meaningful BP reductions and is well tolerated in a black African population. SAHeart 2022;19:6-12
Background: There is no large-scale study that has shown the efficacy of single pill combination (SPC) anti-hypertensive medications in black African population. We therefore evaluated the blood pressure (BP) lowering efficacy and the tolerability of Perindopril plus Amlodipine SPC in black African patients. Methods: It was a multi-centre, prospective, observational programme among hypertensive patients using different doses of Perindopril and Amlodipine. Primary endpoint was assessed as the change in mean sitting systolic and diastolic BPs from baseline to 3 months. Results: 937 patients (55.7% female) were analysed, and the mean age was 56.4 [+ or -] 12.7 years. Systolic and diastolic BPs were significantly reduced by 17.3/9.4mmHg, 21.1/10.8mmHg mmHg and 24.6/12.7mmHg at 4, 8 and 12 weeks respectively compared to baseline value (p Conclusions: Perindopril plus Amlodipine SPC provided clinically meaningful BP reductions and is well tolerated in a black African population. SAHeart 2022;19:6-12